SCHEMBL5209871

SCHEMBL5209871

CCOC(=O)[C@H](O)c1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.53
CA12 O43570 4/20 0.53
CA1 P00915 4/20 0.53
CA2 P00918 4/20 0.53
CA7 P43166 4/20 0.53
CA9 Q16790 4/20 0.53
CA14 Q9ULX7 4/20 0.53
ESR2 Q92731 3/20 0.53
HIF1A Q16665 1/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
CHRM1 P11229 2/20 0.45
SLC6A2 P23975 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CYP1A2 P05177 1/20 0.45
PGR P06401 1/20 0.45
CHRM2 P08172 1/20 0.45
CYP3A4 P08684 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
AR P10275 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5209865 1.00 ESR1 (0.53) ESR1CA12CA1CA2CA7
SCHEMBL11838247 0.95 HIF1A (0.50) ESR1CA12CA1CA2CA7
SCHEMBL13557323 0.86 MEN1 (0.47) LMNACYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL13924144 0.85 SMN1; SMN2 (0.50) LMNATDP1ALOX15KMT2AKDM4E
SCHEMBL512526 0.83 MAPT (0.47) LMNAMAPTTDP1CYP1A2CYP2C9
SCHEMBL898279 0.83 MAPT (0.47) LMNAMAPTTDP1CYP1A2CYP2C9
SCHEMBL2798571 0.83 CA12 (0.48) CA12CA1CA2CA9LMNA
SCHEMBL982864 0.83 LMNA (0.55) LMNAMAPTTDP1CYP1A2CYP3A4
SCHEMBL28421759 0.83 OPRM1 (0.39) LMNATDP1OPRM1KMT2ATSHR
SCHEMBL1395571 0.82 CA12 (0.55) ESR1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023077166-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION MATTERWORKS INC (US) 2023-05-04 WO disclosed
EP-1040102-B1 ARYLTHIAZOLIDINEDIONE DERIVATIVES MERCK & CO INC (US) 2007-01-24 EP disclosed
EP-1194146-B1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES MERCK & CO INC (US) 2006-07-19 EP disclosed
CN-1214035-C Surface-active photoinitiators CIBA SC HOLDING AG (CH) 2005-08-10 CN disclosed
US-6906113-B2 Surface-active photoinitiators CIBA SPECIALTY CHEMICALS CORP. (US) 2005-06-14 US disclosed
US-6828317-B2 Bactericides; gramnegative, grampositive bacteria PHARMACIA & UPJOHN COMPANY 2004-12-07 US disclosed
EP-1472247-A1 ANTIMICROBIAL THIADIAZINONE DERIVATIVES USEFUL IN TREATMENT OF BACTERIAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
US-20040014832-A1 Surface-active photoinitiators CIBA SPECIALTY CHEMICALS CORP. 2004-01-22 US disclosed
US-20040014746-A1 Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections LEUHR GARY W (US) 2004-01-22 US disclosed
CN-1447814-A Surface-active photoinitiators CIBA SC HOLDING AG (CH) 2003-10-08 CN disclosed
EP-1194146-A1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES Merck & Co., Inc. (US) 2002-04-10 EP disclosed
WO-2002014326-A1 SURFACE-ACTIVE PHOTOINITIATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-02-21 WO disclosed
US-6200998-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS; ANTICHOLESTEROL, ANTIDIABETIC AND ANTIOBESITY AGENTS MERCK & CO., INC. 2001-03-13 US disclosed
CN-1282325-A Arylthiazolidinedione derivatives MERCK & CO INC (US) 2001-01-31 CN disclosed
WO-2000078312-A1 ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES MERCK & CO., INC. (US) 2000-12-28 WO disclosed
EP-1040102-A1 ARYLTHIAZOLIDINEDIONE DERIVATIVES Merck & Co., Inc. (US) 2000-10-04 EP disclosed
US-6008237-A POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS MERCK & CO., INC. (US) 1999-12-28 US disclosed
WO-1999032465-A1 ARYLTHIAZOLIDINEDIONE DERIVATIVES MERCK & CO., INC. (US) 1999-07-01 WO disclosed
US-4339594-A HYDROGENATION, HYDROGENATION CATALYSTS HOECHST AKTIENGESELLSCHAFT (DE) 1982-07-13 US disclosed
US-3983160-A Process for the preparation of hydroxyphenylacetonitriles BAYER AKTIENGESELLSCHAFT (DT) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014746-A1 Antimicrobial thiadiazinone derivatives and their application for treatment of bacterial infections TBCD, THPO, NISCH ESR1 4486/4885CA12 4879/4885CA1 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.